New approaches to federal drug sentencing are being proposed by researchers who argue that current U.S. Sentencing Guidelines overemphasize drug quantity while underweighting individual culpability. The debate matters: in early 2025, drug offenses made up roughly 30% of people sentenced in federal courts and 44% of the federal prison population. The result, critics say, can produce punishments that feel blunt and unequal rather than calibrated to harm.
In a new article published in Federal Sentencing Reporter, Jonathan P. Caulkins of Carnegie Mellon University and colleagues examine two recurring problems. The first is the mismatch between how much drug weight a defendant possessed and how central they were to the supply chain. The second is whether sentencing tables treat different drugs with similar harm equivalence, even when their social and physiological impacts differ.
The authors propose a culpability-based theory for sanctioning participants in illicit drug markets. Instead of treating quantity as a dominant proxy for wrongdoing, their framework links recommended sentences to the role an offender played in facilitating access to drugs—particularly the degree to which they helped others obtain harmful substances.
A central technical proposal is to replace the current single quantity table logic with a three-table structure. One table would be used when a defendant’s organizational role cannot be reliably established, producing intermediate guideline ranges. Two additional tables would separate defendants whose roles suggest higher or lower culpability, including those who owned drugs or held key positions versus individuals with minor or irregular participation.
To avoid over-penalizing low-level involvement, the model assigns shorter sentences for minor roles such as couriers, especially when employment resembles piece-rate or gig-like arrangements. The goal is not to abandon guideline structure, but to redirect scarce prison capacity toward higher-impact actors.
The researchers also argue that drug weighting should reflect harm potential rather than conventional categories alone. They outline an alternative approach for psychostimulants—such as methamphetamine and cocaine—and opioids—such as fentanyl and heroin—by focusing on harms associated with each drug type.
Quantity measurement, they add, should be improved. One suggestion imputes drug weight from cash on hand at the time of arrest. This aims to reduce arbitrary sentencing shifts caused by arrest timing—for example, punishing a person less for having fewer remaining drugs after a sale, even if they are otherwise comparable.
Overall, the authors contend that combining role-sensitive tables with more robust harm-based drug comparisons and refined quantity estimation could enable substantial guideline revision while maintaining the system’s basic architecture.
Subject of Research: Federal drug sentencing guidelines; drug policy; culpability-based sentencing; harm-based drug equivalence
Article Title: Revising Federal Drug Sentencing Guidelines to Better Match Sanctions to Harms Available to Purchase
News Publication Date: 19-May-2026
Web References: http://dx.doi.org/10.1215/10539867-12442726
References: Federal Sentencing Reporter; DOI: 10.1215/10539867-12442726
Image Credits: Not provided in the provided content.
Keywords: U.S. Sentencing Guidelines; drug sentencing; culpability; harm-based sentencing; methamphetamine; cocaine; fentanyl; heroin; sentencing reform; federal sentencing policy
